All In Biotech

Drug Trial Radar · NCT05870540

BPL-003 Efficacy and Safety in Treatment Resistant Depression

A Quadruple Masked, Dose-Finding Study to Evaluate the Efficacy and Safety of Intranasal BPL-003, With Open Label Extension, in Patients With Treatment-Resistant Depression

Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 196 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

196

Actual

Start

Sep 14, 2023

Primary completion

Mar 28, 2025

Study completion Jul 3, 2025

Sponsor

Lead sponsor
Beckley Psytech LimitedIndustry
Sponsor type
Industry
First posted
May 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2 study randomized, quadruple-masked, multi-center trial with an open-label extension (OLE), designed to investigate the efficacy and safety of BPL-003 in patients with treatment resistant depression (TRD).

Conditions

  • Treatment Resistant Depression

Interventions

  • BPL-003Drug

    A single dose administered intranasally

  • BPL-003Drug

    A single dose administered intranasally (administered as 2 nasal sprays, 10 minutes apart)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Core: Change From Baseline in Montgomery and Asberg Depression Rating Scale (MADRS) Total Score at Day 29 (12 mg vs 0.3 mg BPL-003)Time frame: 4 weeks
  2. OLE: Number of Participants With Treatment-emergent Adverse Events in the OLETime frame: 8 weeks

Locations

42 sites in 6 countries. Site status is shown where the registry gives one.

  • UAB School of Public Health, Department of Health Behavior

    Birmingham, Alabama

  • Woodland Research Northwest

    Rogers, Arkansas

  • Kadima Neuropsychiatry Institute

    San Diego, California

  • San Francisco Insight and Integration Center

    San Francisco, California

  • Pacific Neuroscience Institute, Treatment and Research in Psychedelics (TRIP) Program

    Santa Monica, California

  • Wholeness Center

    Fort Collins, Colorado

  • Segal Trials Center for Psychedelic and Cannabis Research

    Lauderhill, Florida

  • Emory University, Brain Health Center, Department of Psychiatry and Behavioral Sciences

    Atlanta, Georgia

  • CenExel ACMR

    Atlanta, Georgia

  • CenExel iResearch

    Decatur, Georgia

  • Sunstone Medical PC (Sunstone Therapies / Aquilino Cancer Center)

    Rockville, Maryland

  • Boston Clinical Trials

    Boston, Massachusetts

  • CenExel HRI

    Berlin, New Jersey

  • New York State Psychiatric Institute

    New York, New York

  • Portland Psychotherapy

    Portland, Oregon

  • Insite clinical research

    DeSoto, Texas

  • AIM Trials

    Plano, Texas

  • Cedar Clinical Research

    Draper, Utah

  • University of Wisconsin, Dept of Family Medicine & Community Health

    Madison, Wisconsin

  • NeuroCentrix Research

    Melbourne, Australia

  • Royal Melbourne Hospital, University of Melbourne

    Parkville, Australia

  • Royal Prince Alfred Hospital

    Sydney, New South Wales, Australia

  • Dept. of Psychiatry and School Psychological Sciences, Monash University

    Clayton, Victoria, Australia

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany

  • OVID Clinic, Augmented Psychotherapy

    Berlin, Germany

  • Department of Psychiatry, University Hospital Frankfurt

    Frankfurt am Main, Germany

  • Central Institute of Mental Health, Dept. of Molecular Neuroimaging

    Mannheim, Germany

  • Universitätsklinik für Psychiatrie und Psychotherapie, Calwerstr. 14

    Tübingen, Germany

  • Department of Psychiatry, UCK

    Gdansk, Poland

  • Centrum Badań Klinicznych PI-House sp. z o.o.

    Gdansk, Poland

  • SPZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi

    Lodz, Poland

  • Klinika Inventiva

    Tuszyn, Poland

  • Department of Pharmacology and Physiology of CNS

    Warsaw, Poland

  • Hospital del Mar

    Barcelona, Spain

  • Parc Sanitari Sant Joan de Deu HD Numancia

    Barcelona, Spain

  • Hospital Clinic de Barcelona, Psychiatry and Psychology Dept.

    Barcelona, Spain

  • Fundación de Investigación HM Hospital

    Madrid, Spain

  • Centro de Salud Mental La Corredoria

    Oviedo, Spain

  • Centro Salud San Juan

    Salamanca, Spain

  • NIHR Exeter Clinical Research Facility

    Exeter, United Kingdom

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.